132 related articles for article (PubMed ID: 36977322)
1. INCIDENCE AND TIMING OF PIGMENT EPITHELIAL DETACHMENT AND SUBRETINAL FLUID DEVELOPMENT IN TYPE 3 MACULAR NEOVASCULARIZATION ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION.
Kim JH; Kim JW; Kim CG
Retina; 2023 Aug; 43(8):1264-1273. PubMed ID: 36977322
[TBL] [Abstract][Full Text] [Related]
2. EFFECT OF RANIBIZUMAB AND AFLIBERCEPT ON RETINAL PIGMENT EPITHELIAL DETACHEMENT, SUBRETINAL AND INTRARETINAL FLUID IN AGE-RELATED MACULAR DEGENERATION.
Sumarová P; Ovesná P; Matušková V; Beránek J; Michalec M; Michalcová L; Autrata D; Vysloužilová D; Chrapek O
Cesk Slov Oftalmol; 2022; 78(4):176-185. PubMed ID: 35922146
[TBL] [Abstract][Full Text] [Related]
3. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW
Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779
[TBL] [Abstract][Full Text] [Related]
4. Spatial Correspondence Between Intraretinal Fluid, Subretinal Fluid, and Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration.
Klimscha S; Waldstein SM; Schlegl T; Bogunovic H; Sadeghipour A; Philip AM; Podkowinski D; Pablik E; Zhang L; Abramoff MD; Sonka M; Gerendas BS; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4039-4048. PubMed ID: 28813577
[TBL] [Abstract][Full Text] [Related]
5. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
[TBL] [Abstract][Full Text] [Related]
6. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
8. SUBRETINAL FLUID ASSOCIATED WITH DRUSENOID PIGMENT EPITHELIAL DETACHMENT.
Cho HJ; Jeon YJ; Yoon W; Lee J; Kim J; Kim CG; Kim JW
Retina; 2023 Aug; 43(8):1274-1281. PubMed ID: 36996466
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of Functional and Morphological Outcome after Aflibercept or Ranibizumab in Chronic Recurrent Neovascular Age-Related Macular Degeneration].
Hoffmann AE; Maier M; Lohmann CP; Feucht N
Klin Monbl Augenheilkd; 2016 Nov; 233(11):1260-1265. PubMed ID: 27130974
[No Abstract] [Full Text] [Related]
10. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
11. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
12. Difference in characteristics and lesion reactivation between type 3 macular neovascularization with and without subretinal fluid at baseline.
Kim JH; Kim JW; Kim CG
Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):401-408. PubMed ID: 36112220
[TBL] [Abstract][Full Text] [Related]
13. Non-neovascular age-related macular degeneration with subretinal fluid.
Hilely A; Au A; Freund KB; Loewenstein A; Souied EH; Zur D; Sacconi R; Borrelli E; Peiretti E; Iovino C; Sugiura Y; Ellabban AA; Monés J; Waheed NK; Ozdek S; Yalinbas D; Thiele S; de Moura Mendonça LS; Lee MY; Lee WK; Turcotte P; Capuano V; Filali Ansary M; Chakravarthy U; Lommatzsch A; Gunnemann F; Pauleikhoff D; Ip MS; Querques G; Holz FG; Spaide RF; Sadda S; Sarraf D
Br J Ophthalmol; 2021 Oct; 105(10):1415-1420. PubMed ID: 32920528
[TBL] [Abstract][Full Text] [Related]
14. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
Zinkernagel MS; Wolf S; Ebneter A
Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
[TBL] [Abstract][Full Text] [Related]
15. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
[TBL] [Abstract][Full Text] [Related]
16. Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.
Chan CK; Abraham P; Sarraf D; Nuthi AS; Lin SG; McCannel CA
Eye (Lond); 2015 Jan; 29(1):80-7. PubMed ID: 25277305
[TBL] [Abstract][Full Text] [Related]
17. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
[TBL] [Abstract][Full Text] [Related]
18. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
Chan CK; Jain A; Sadda S; Varshney N
Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
[TBL] [Abstract][Full Text] [Related]
19. QUANTITATIVE ANALYSIS OF PIGMENT EPITHELIAL DETACHMENT RESPONSE TO DIFFERENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN WET AGE-RELATED MACULAR DEGENERATION.
Balaskas K; Karampelas M; Horani M; Hotu O; Keane P; Aslam T
Retina; 2017 Jul; 37(7):1297-1304. PubMed ID: 27755376
[TBL] [Abstract][Full Text] [Related]
20. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
